Buy CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) – Premium Growth Hormone Peptide for Recovery Research
Product Overview
CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) delivers research-grade Modified GRF (1-29), a potent GHRH analogue stimulating pulsatile growth hormone release without the prolonged action of DAC versions. This 5mg lyophilized vial from Ultima Pharmaceuticals supports investigations into GH/IGF-1 axis activation, ideal for studies on muscle repair, fat metabolism, and endocrine response in performance models. Researchers favor CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) for its short 30-minute half-life, enabling precise multiple daily administrations mimicking natural GH pulses.
HPLC-tested at 99.2% purity, CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) reconstitutes easily in bacteriostatic water for subcutaneous research protocols. Unlike longer-acting peptides, the no-DAC structure prevents receptor desensitization, making CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) optimal for sustained GH secretion studies over 8-12 weeks. Strictly for laboratory research only, not for human or veterinary use; institutional compliance required.
Performance research highlights CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) for synergistic effects when stacked with GHRPs, amplifying GH peaks up to 10-fold over baseline. International discreet shipping arrives in 3-5 days to USA/UK—select options at checkout.
Benefits and Uses
CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) amplifies endogenous GH pulses, driving protein synthesis, lipolysis, and connective tissue repair in research applications.
-
Elevates natural GH secretion 5-10x for muscle hypertrophy studies.
-
Accelerates fat oxidation while preserving lean mass during caloric deficits.
-
Enhances deep sleep architecture and recovery hormone optimization.
-
Promotes collagen synthesis for joint and tendon research.
-
Improves insulin sensitivity and nutrient partitioning efficiency.
-
Supports anti-aging biomarkers through IGF-1 pathway activation.
Dosage and Administration
Research protocols reconstitute CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) with 2-3ml bacteriostatic water, yielding 166-250mcg per 0.1ml. Standard dosing explores 100mcg 2-3x daily (morning, post-workout, bedtime), leveraging the ~30-minute half-life for multiple pulses. Advanced studies test 200mcg per injection, totaling 300-600mcg daily via insulin syringe subcutaneous administration into abdominal fat.
Cycles typically run 8-12 weeks followed by 4-week breaks to prevent pituitary downregulation; rotate injection sites. Stacking ratios with Ipamorelin (1:1 to 1:2) maximize synergy. Female research uses identical protocols. Full medical and legal disclaimer: CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) is strictly for research only, not for human consumption. Non-research use violates regulations and poses health risks.
Cycle Examples and Stacks
-
Beginner Solo: 100mcg 2x/day CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT), 8 weeks – GH pulse frequency research.
-
Intermediate: 100mcg CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) + 100mcg Ipamorelin 3x/day, 10 weeks – synergistic GH amplification.
-
Advanced: 200mcg CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) + 200mcg Ipamorelin + 200mcg GHRP-6 3x/day, 12 weeks – maximal GH/IGF-1 axis stimulation.
-
Women: 100mcg 2x/day CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) solo, 8 weeks – recovery and body composition studies.
Side Effects and Precautions
CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) primarily causes transient injection site reactions or water retention from GH spikes; prolactin elevation minimal without GHRP stacking. Monitor IGF-1 levels quarterly, avoiding use in cancer models due to mitogenic potential. Hypoglycemia possible during peak GH pulses—time injections pre-meal.
-
Common: Flushing, lethargy 20-30 minutes post-injection.
-
Monitor: Serum IGF-1, glucose tolerance, pituitary function.
-
Avoid if: Active neoplasia, carpal tunnel syndrome, glucose dysregulation.
-
Legal note: Research chemical only; human use prohibited.
Why Choose CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT)?
CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) achieves 99.2% HPLC purity, eliminating underdosed generics common in peptide research. Ultima’s lyophilization preserves full bioactivity unlike heat-degraded alternatives.
Competitors frequently test 85-92% purity with sequence impurities; CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) provides third-party CoA verification. The 5mg vial format optimizes 8-12 week protocols economically. International discreet shipping 3-5 days to USA/UK ensures research continuity—select at checkout.
FAQ
What is the half-life of CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT)?
~30 minutes, requiring 2-3x daily dosing for sustained GH pulses.
Can CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) be stacked?
Optimal 1:1 with Ipamorelin or GHRP-2/6 for 5-10x GH synergy.
Is CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) safe for beginners?
Yes, start 100mcg 2x/day; minimal sides compared to DAC version.
What about shipping for CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT)?
3-5 days discreet international to USA/UK; checkout options available.
Does CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) cause water retention?
Mild from GH spikes; less than long-acting GHRH analogues.
How is CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) purity proven?
99.2% HPLC with mass spectrometry sequence confirmation.
Women’s use of CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT)?
100mcg 2x/day effective for body comp research; no virilization.
Is CJC1295 no DAC Ultima Pharmaceuticals 5mg/vial (INT) legal?
Research only, not for human use; verify local research chemical laws.
